SCHEMBL3965635

SCHEMBL3965635

Cc1cc(Nc2cc3c(C)cccc3c(Oc3ccc(F)cc3)n2)n[nH]1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AURKA O14965 9/20 0.47
GSK3B P49841 3/20 0.47
SRC P12931 2/20 0.47
NTRK1 P04629 4/20 0.44
AURKB Q96GD4 7/20 0.44
JAK2 O60674 3/20 0.43
CYP3A4 P08684 3/20 0.43
CYP2C8 P10632 3/20 0.43
CYP2C9 P11712 3/20 0.43
JAK1 P23458 3/20 0.43
TYK2 P29597 3/20 0.43
CYP2C19 P33261 3/20 0.43
JAK3 P52333 3/20 0.43
ADORA3 P0DMS8 2/20 0.43
CYP1A2 P05177 1/20 0.43
EIF2AK2 P19525 1/20 0.42
GSK3A P49840 1/20 0.42
PIK3C3 Q8NEB9 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3964294 0.91 AURKA (0.47) AURKAGSK3BSRCNTRK1AURKB
SCHEMBL3965435 0.90 AURKA (0.48) AURKAGSK3BSRCAURKBPIK3C3
SCHEMBL3972210 0.90 AURKA (0.56) AURKAGSK3BSRCAURKBCYP3A4
SCHEMBL3968571 0.89 AURKA (0.52) AURKAGSK3BSRCNTRK1AURKB
SCHEMBL3964942 0.89 GSK3B (0.45) AURKAGSK3BSRCNTRK1AURKB
SCHEMBL3968799 0.87 AURKA (0.52) AURKAGSK3BSRCNTRK1AURKB
SCHEMBL3961680 0.83 AURKA (0.47) AURKAGSK3BSRCAURKBEIF2AK2
SCHEMBL3967470 0.83 AURKA (0.48) AURKAGSK3BSRCAURKBPIK3C3
SCHEMBL3961779 0.82 AURKA (0.48) AURKAGSK3BSRCNTRK1AURKB
SCHEMBL3964043 0.81 AURKA (0.43) AURKAGSK3BSRCNTRK1AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US claimed
EP-1966190-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP claimed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US claimed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 WO claimed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
EP-1966190-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 WO disclosed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179151-A1 Isoquinoline aminopyrazole derivatives CYP3A5, CYP3A43, CYP3A4 AURKA 1165/4885GSK3B 842/4885SRC 1926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.